

Synthesis and Bone Resorption Effect of Alkoxy-Substituted Xanthenes

Giorgio Pifferi^{a)}, Paolo Da Re^{a)}, Piero Valenti^{*b)}, Alessandra Bisi^{b)}, and Salvatore Malandrino^{c)}

^{a)} Institute of Pharmaceutical Chemistry, University of Milan, Viale Abruzzi 42, 20131 Milan, Italy

^{b)} Department of Pharmaceutical Sciences, University of Bologna, Via Belmeloro 6, 40126 Bologna, Italy

^{c)} Inverni della Beffa, R&D Laboratories, Via Ripamonti 99, 20141 Milan, Italy

Key Words : Ipriflavone; alkoxyxanthenes; bone resorption inhibition


Summary

A topological modification of ipriflavone **1**, a recent anti-osteoporotic drug, is described. The flavone moiety of **1** has been replaced by a xanthone one. Among the new derivatives, the 3,6-diisopropoxyxanthone (**2a**) has shown significant bone resorption inhibition in *in vitro* and *in vivo* tests.

Introduction

Osteoporosis is the pathological term used to describe skeletal abnormalities that arise from a loss of a bone mass^[1,2]. Osteoporosis is common in elderly women and is asymptomatic until it is complicated by a fracture or a permanent bone remodelling deformity in the vertebral bodies. Since these abnormalities are caused by an imbalance between bone resorption and formation, therapeutic regimens aim to control, at cellular level, the osteoclastic and osteoblastic remodelling activities. Most drugs used in therapy belong to the antiresorptive class, while those that increase bone formation are rarely used due to possible toxic effects.

Among derivatives of the first class such as estrogens, calcium, calcitonin, and bisphosphonates, we singled out ipriflavone **1** (7-isopropoxyisoflavone)^[3,4] because it belongs to the large family of flavonoids that has interested us for some time^[5]. In particular, we wished to verify in this field of medicinal chemistry the validity of the conversion of a biologically active flavone into a xanthone. This transformation, which may be regarded as a quasi-isomerization, had been successfully undertaken amongst analeptics^[6], adrenergics^[7], and cytotoxic agents^[8]. In the present case the result of the above transformation stays the same even when the parent compound is an isoflavone.



With this aim we have prepared two xanthone derivatives **2a** and **2b**, where compound **2a** may be viewed as a Siamese twin drug^[9].

Results and Discussion

On the basis of a preliminary screening on human osteoblastic sarcoma cells proliferation assay^[10], compound **2a** was selected and evaluated through *in vitro* and *in vivo* tests.

Its effect on bone resorption was studied *in vitro* according to Zamboni-Zallone *et al.*^[11] and measured according to Blair *et al.*^[12] using ³H-proline prelabeled rat bone; the results are shown in Table 1.

Table 1. Effect of compound **2a** on bone resorption of hen osteoclasts.

Compound	Conc. mg/ml	Bone resorption (mg)	
		24 h	48 h
Controls (DMSO)	–	44 ± 7.5	72.7 ± 9.6
1	25	25.5 ± 1	22.4 ± 1.0*
2a	10	32.1 ± 3	50.2 ± 6.3
	25	16.0 ± 1.0*	21.0 ± 1.0*

n = 4; * *p* < 0.01.

At concentrations of 10 and 25 mg/ml, **2a** showed a dose dependent activity. Bone resorption inhibition was in fact 60% higher than in unexposed controls, both at 24 and at 48 h. Significance was evaluated by Student's *t* test versus the group treated with just the solvent (control).

In vivo, the antiosteoporotic activity of **2a**, administered orally, was evaluated on suckling rats placed on a hypocalcic diet according to the slightly modified method disclosed by Lozupane *et al.*^[13].

Table 2. The *in vivo* activity of compound **2a**.

Compd	Dose (mg/kg/oral)	Compacts thickness			
		Diaphysis mm ± S.D.	%	Methaphysis mm ± S.D.	%
Control (Methocel 0.5%)	–	0.55 ± 0.04	–	0.31 ± 0.08	–
2a	250	0.71 ± 0.03*	+29	0.040 ± 0.12*	+29

n = 3; * *p* < 0.05.

The results are reported in Table 2. Compound **2a** showed significant antiosteoporotic activity: the diaphysis and metaphysis both revealed a thickness that was 29% higher than that of the control group.

The acute toxicity of **2a** was evaluated in the rat after oral and intraperitoneal administration, and the LD₅₀ was calculated with probit methods^[14]. Compound **2a** has an LD₅₀>4000 mg/kg (LD₀) after oral administration and an LD₅₀>1000 mg/kg (LD₂₀) through the intraperitoneal route.

Therefore, we believe that our working hypothesis is confirmed and that **2a** represents a significant improvement of the antiosteoporotic activity of ipriflavone suggesting further structural modifications of the parent compound.

Experimental

Melting points were determined on a Büchi apparatus and are uncorrected. ¹H and ¹³C NMR spectra were obtained for CDCl₃ solutions on a Gemini 300 spectrometer. Elemental analysis were within ± 0.4% of the theoretical value. Mass spectra were recorded on a V.G. 7070 E spectrometer.

3,6-Di(isopropoxy)xanthen-9-one (**2a**)

A mixture of 27.5 g (0.121 mol) of 3,6-dihydroxyxanthen-9-one^[15], 54.6 ml (0.546 mol) of isopropyl bromide and 27.5 g of *N*-benzyltriethylammonium chloride in 1 l toluene and 580 ml of 50% aqueous sodium hydroxide was refluxed under stirring for 5 h. The mixture was cooled to room temperature and the organic phase was separated, washed with water to neutrality, dried on sodium sulphate and evaporated. The residue was crystallized from ligroin to yield 31 g (84%) of **2a**, mp 135–36 °C. Anal. (C₁₉H₂₀O₄). ¹H NMR δ: 1.44 (d, 12H), 4.7 (m, 2H), 6.9 (m, 4H), 8.22 (d, 2H). ¹³C NMR δ: 22.76; 71.55; 102.47; 114.71; 116.40; 129.02; 159.93; 163.97; 176.36. MS: *m/z* (relative abundance): 312 (M⁺, 20.18), 229 (13.33), 228 (100), 200 (7.35), 199 (7.46), 57 (5.50), 43 (22.60), 41 (16.69), 39 (6.23), 32 (44.78).

3-Isopropoxyxanthen-9-one (**2b**)

Using the same procedure and starting from 3-hydroxyxanthen-9-one^[16] (21.2 g, 0.1 mol), 22.8 g (90%) of **2b**, mp 89–90 °C (ligroin) [lit.^[17] mp 90–92 °C]. Anal. (C₁₆H₁₄O₃). ¹H NMR δ: 1.42 (d, 6H), 4.7 (m, 1H), 6.8–8.4 (m, 7H). ¹³C NMR δ: 22.56; 71.44; 102.17; 114.93; 116.11; 118.35; 122.62; 124.44; 127.25; 128.89; 134.86; 156.84; 158.73; 164.23; 176.83. MS: *m/z* (relative abundance): 254 (M⁺, 25.40), 213 (13.83), 212 (100), 184 (10.82), 155 (6.58), 128 (6.64), 127 (6.39), 70 (6.54), 63 (6.99), 57 (8.43), 43 (9.17), 41 (9.44), 32 (23.02).

References

- [1] B.L. Riggs, I.J. Melton, *N. Engl. J. Med.* **1992**, 327, 620.
- [2] *Handbook of Experimental Pharmacology*, Vol. 107, Physiology and Pharmacology of Bone, G.R. Mundy and T.J. Martin Editors, Springer Verlag, Berlin, 1993.
- [3] *Drugs Fut.* **1986**, 996.
- [4] G. Lanyi, M. Nogradi, M. Escery-Puskas, I. Hermecz, *Acta Pharm. Hung.* **1995**, 65, 191.
- [5] F. Ursini, M. Maiorino, P. Morazzoni, A. Roveri, G. Pifferi, *Free Rad. Biol. Med.* **1994**, 16, 547.
- [6] P. Da Re, L. Sagromora, V. Mancini, P. Valenti, L. Cima, *J. Med. Chem.* **1970**, 13, 527.
- [7] P. Da Re, P. Valenti, A. Borracchini, G.P. Primofiore, *J. Med. Chem.* **1972**, 15, 198.
- [8] P. Valenti, P. Da Re, A. Rampa, P. Montanari, M. Carrara, L. Cima *Anti-Cancer Drug Design*, **1993**, 8, 349.
- [9] T.J. Bourguignon in *The Practice of Medicinal Chemistry*, C.G. Warmonth, Ed. Academic Press **1966**, p. 261.
- [10] G. Pifferi, P. Da Re, P. Valenti, A. Bisi, *Il Farmaco*, **1996**, 51, 689.
- [11] A. Zamboni-Zallone, A. Teti, M.V. Primavera, *Anat. Embriol.*, **1982**, 165, 405.
- [12] H.C. Blair *et al.*, *J. Cell Biol.* **1986**, 102, 1164.
- [13] E. Lozupane, A. Favis, *Bone* **1988**, 9, 215.
- [14] D. J. Finney in *Probit Analysis*, Cambridge University Press, 3rd Ed., Cambridge, 1971.
- [15] P.K. Grover, G.D. Shah, R.C. Shah, *J. Chem. Soc.* **1955**, 3982.
- [16] F. Ullmann, W. Denzler, *Ber. Dtsch. Chem. Ges.* **1906**, 39, 4332.
- [10] P. Valenti, S. Salvadorini, P. Da Re, L. Cima, *Eur. J. Med. Chem. Chimica Therapeutica* **1975**, 10, 390.

Received: February 14, 1997 [FP189]

© WILEY-VCH Verlag GmbH, D-69451 Weinheim, 1997 – Printed in the Federal Republic of Germany

Anzeigenleitung: H.-G. Schwarz, D-69451 Weinheim – WILEY-VCH Verlag GmbH, Postfach 10161, D-69451 Weinheim.

Alle Rechte, insbesondere die der Übersetzung in fremde Sprachen, vorbehalten. Kein Teil dieser Zeitschrift darf ohne schriftliche Genehmigung des Verlages in irgendeiner Form – durch Fotokopie, Mikrofilm oder irgendein anderes Verfahren – reproduziert oder in eine von Maschinen, insbesondere von Datenverarbeitungsmaschinen verwendbare Sprache übertragen oder übersetzt werden. – All rights reserved (including those of translation into foreign languages). No part of this issue may be reproduced in any form – photoprint, microfilm, or any other means – nor transmitted or translated into a machine language without the permission in writing of the publishers. – Von einzelnen Beiträgen oder Teilen von ihnen dürfen nur einzelne Vervielfältigungsstücke für den persönlichen und sonstigen eigenen Gebrauch hergestellt werden. Die Weitergabe von Vervielfältigungen, gleichgültig zu welchem Zweck sie hergestellt werden, ist eine Urheberrechtsverletzung. Der Inhalt dieses Heftes wurde sorgfältig erarbeitet. Dennoch übernehmen Autoren, Herausgeber, Redaktion und Verlag für die Richtigkeit von Angaben, Hinweisen und Ratschlägen sowie für eventuelle Druckfehler keine Haftung. This journal was carefully produced in all its parts. Nevertheless, authors, editors and publishers do not warrant the information contained therein to be free of errors. Readers are advised to keep in mind that statements, data, illustrations, procedural details or other items may inadvertently be inaccurate. – Die Wiedergabe von Gebrauchsnamen, Handelsnamen, Warenbezeichnungen u. dgl. in dieser Zeitschrift berechtigt nicht zu der Annahme, daß solche Namen ohne weiteres von jedermann benutzt werden dürfen. Es handelt sich häufig um gesetzlich eingetragene Warenzeichen, auch wenn sie in dieser Zeitschrift nicht als solche gekennzeichnet sind. Druck und Buchbinder: Druck Partner Rübelmann GmbH, D-69502 Hemsbach. – Unverlangt zur Rezension eingehende Bücher werden nicht zurückgesandt.

For USA and Canada: Archiv der Pharmazie (ISSN 0365-6233) is published monthly. – Printed in the Federal Republic of Germany.

US Postmaster: Periodicals postage paid at Jamaica, NY 11431. Air freight and mailing in the USA by Publications Expediting Services Inc., 200 Meacham Ave., Elmont NY 11003. Send address changes to: "Archiv der Pharmazie", c/o Publications Expediting Services Inc., 200 Meacham Ave., Elmont NY 11003

Valid for users in the USA: The appearance of the code at the bottom of the first page of an article in this journal (serial) indicates the copyright owner's consent that copies of the article may be made for personal or internal use, or for the personal or internal use of specific clients. This consent is given on the condition, however, that copier pay the stated per copy fee through the Copyright Clearance Center, Inc., for copying beyond that permitted by Sections 107 for 108 of the U.S. Copyright Law. This consent does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective work, or for resale. For copying from back volumes of this journal see »Permissions to Photo-Copy: Publisher's Fee List« of the CCC.

Printed on chlorine- and acid-free paper/Gedruckt auf säurefreiem und chlorfrei gebleichtem Papier